Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

New Therapies of Neovascular AMD – Beyond Anti VEGFs

Version 1 : Received: 10 June 2018 / Approved: 12 June 2018 / Online: 12 June 2018 (06:26:56 CEST)

A peer-reviewed article of this Preprint also exists.

Yerramothu, P. New Therapies of Neovascular AMD—Beyond Anti-VEGFs. Vision 2018, 2, 31. Yerramothu, P. New Therapies of Neovascular AMD—Beyond Anti-VEGFs. Vision 2018, 2, 31.


Neovascular age-related macular degeneration (nAMD) accounts for one of the leading causes of blindness among the aging population. The current treatment options for nAMD include intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF). However, standardised frequent administration of anti-VEGF injections only improves the vision in approximately 30%-40% of nAMD patients. Current therapies targeting nAMD pose a significant risk of retinal fibrosis and geographic atrophy (GA) development in nAMD patients. A need exists to develop new therapies to treat nAMD with effective and long-term anti-angiogenic effects. Recent research on nAMD has discovered novel therapeutic targets and angiogenic signalling mechanisms involved in its pathogenesis. For example, tissue factor, human intravenous immune globulin, interferon-β signalling, cyclooxygenase-2 (COX-2) and cytochrome P450 monooxygenase lipid metabolites have been identified as key players in the development of angiogenesis in AMD disease models. Furthermore, novel therapies such as NLRP3 inflammasome inhibition, targeted intraceptor nanoparticle therapy, inhibitors of integrins and tissue factor are currently being tested at the level of clinical trials to treat nAMD. The aim of this review is to discuss the scope for alternative therapies proposed to anti-VEGFs for the treatment of nAMD.


neovascular AMD; new therapies; anti-VEGFs; AMD signalling


Medicine and Pharmacology, Ophthalmology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.